Mason Investment Advisory Services’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$262K Buy
285
+15
+6% +$15.2K 0.01% 67
2025
Q4
$290K Sell
270
-61
-18% -$58.3K 0.01% 64
2025
Q3
$252K Hold
331
0.01% 71
2025
Q2
$258K Buy
331
+1
+0.3% +$777 0.01% 68
2025
Q1
$273K Buy
330
+60
+22% +$49.9K 0.02% 65
2024
Q4
$208K Buy
270
+1
+0.4% +$828 0.01% 71
2024
Q3
$239K Sell
269
-16
-6% -$14.4K 0.01% 67
2024
Q2
$258K Buy
285
+16
+6% +$12.8K 0.02% 62
2024
Q1
$209K Buy
+269
New +$191K 0.01% 66
2021
Q1
Sell
-4,710
Closed -$795K 87
2020
Q4
$795K Hold
4,710
0.1% 49
2020
Q3
$697K Hold
4,710
0.1% 52
2020
Q2
$773K Hold
4,710
0.11% 43
2020
Q1
$653K Sell
4,710
-3,181
-40% -$437K 0.11% 52
2019
Q4
$1.04M Hold
7,891
0.15% 49
2019
Q3
$882K Buy
7,891
+2,481
+46% +$276K 0.14% 56
2019
Q2
$599K Hold
5,410
0.1% 60
2019
Q1
$702K Buy
+5,410
New +$658K 0.19% 55

Other funds holding LLY

Mason Investment Advisory Services's LLY Position: Q1 2026 in Review

Mason Investment Advisory Services increased its Eli Lilly (LLY) stake by 5.6% in Q1 2026, buying an estimated $15.2K and bringing the position to 285 shares worth $262K. The position accounts for 0.01% of the portfolio, ranked #67.

Mason Investment Advisory Services first reported a position in LLY in Q1 2019 and has held it in 17 quarters since. The position peaked at $1.04M in Q4 2019. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Mason Investment Advisory Services held 285 shares of Eli Lilly worth $262K as of Q1 2026.
  • Mason Investment Advisory Services bought 15 Eli Lilly shares in Q1 2026, an estimated $15.2K.
  • Eli Lilly made up 0.01% of Mason Investment Advisory Services's portfolio in Q1 2026, its #67 holding.
  • Mason Investment Advisory Services first reported a position in Eli Lilly in Q1 2019 and has held it in 17 quarters since.
  • Mason Investment Advisory Services's Eli Lilly position peaked at $1.04M in Q4 2019.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Mason Investment Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.